View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 5, 2021

RedHill reports data from Covid-19 clinical trial of opaganib

The data showed 62% statistically significant reduction in mortality and 21% efficacy benefit with opaganib.

RedHill Biopharma has reported new data from the global Phase II/III clinical trial of oral drug opaganib (ABC294640) conducted in patients hospitalised with severe Covid-19 pneumonia.

The latest move follows the completion of enrolment of 475 people for the multi-centre, randomised, double-blind, parallel-arm, placebo-controlled global trail in June this year.

Opaganib is designed to selectively inhibit sphingosine kinase-2 (SK2) and has anti-inflammatory and antiviral properties.

Subjects in the study were randomised at a 1:1 ratio and given either opaganib or placebo on top of the standard-of-care therapy they received.

The new data demonstrated a 62% statistically significant reduction in mortality for moderately severe Covid-19 patients group treated with opaganib versus the placebo-controlled arm.

It also demonstrated a statistically significant efficacy benefit of 21% using opaganib in reaching room air by Day 14, which forms the primary endpoint of the trial.

RedHill stated that the clinical trial data has further shown a median of four days earlier hospital discharge for patients treated with the drug compared to those who received placebo.

This represented a cumulative saving of 524 days of hospitalisation across the patient group by Day 42.

RedHill medical director Mark Levitt said: “These new findings support the potential for opaganib’s use in hospitalised, moderately severe Covid-19 patients, a key group of patients that are at high risk of disease progression, morbidity and mortality, and who may benefit from opaganib’s combined antiviral and anti-inflammatory activities.

“The results provide a strong rationale for opaganib’s potential efficacy in hospitalized patients in need of oxygen supplementation up to 60% FiO2, a large proportion of hospitalised Covid-19 patients.

“The Phase II/III study results are also consistent with opaganib’s earlier US Phase II study results and the demonstrated potent antiviral inhibition of SARS-CoV-2 variants in human bronchial epithelial cells, providing further support for its potential in earlier stages of disease where viral load is higher.”

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy